TY  - GEN
AU  - Papp,K A
AU  - Menter,M A
AU  - Raman,M
AU  - Disch,D
AU  - Schlichting,D E
AU  - Gaich,C
AU  - Macias,W
AU  - Zhang,X
AU  - Janes,J M
TI  - A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
SN  - 1365-2133
PY  - 2017///0613
KW  - Azetidines
KW  - administration & dosage
KW  - Dermatologic Agents
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Janus Kinase 1
KW  - antagonists & inhibitors
KW  - Janus Kinase 2
KW  - Male
KW  - Middle Aged
KW  - Psoriasis
KW  - drug therapy
KW  - Purines
KW  - Pyrazoles
KW  - Sulfonamides
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1111/bjd.14403
ER  -